BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy

Nov 19, 2026

New Preclinical Findings Show TROP2 Levels May Help Predict REQORSA Treatment Response—and That Modifying TROP2 Expression May Increase Cancer Cell Sensitivity to Gene Therapy. Combined With the Roche Diagnostics Collaboration, Expanding TUSC2 Research and Advancing Clinical Programs, Genprex, Inc. (NAS DAQ: GNPX) Is Building Significant Momentum Across Its Innovative Biotechnology Platform.

AUSTIN, Texas - Nov. 19, 2026 - PRLog -- Genprex, Inc. (N A S D A Q: GNPX) $GNPX is bringing another exciting development to its growing gene therapy story with today's November 19 announcement of new preclinical data identifying TROP2 as a potential predictive biomarker for its lead investigational therapy, REQORSA® (quaratusugene ozeplasmid). Presented at the 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, the research offers important new insights into how TROP2 expression may influence the response of non-small cell lung cancer (NSCLC) to REQORSA.

What makes today's announcement especially interesting is that researchers are investigating more than simply whether TROP2 can identify patients likely to respond. The new findings also suggest that changing TROP2 expression may influence how cancer cells respond to TUSC2 gene therapy, potentially opening another avenue for improving treatment sensitivity.

For Genprex investors, this represents an important addition to an increasingly sophisticated precision-oncology strategy. The company is working to combine its innovative gene therapy platform with biomarker research that could help researchers better understand treatment response and identify patients who may benefit most.

Today's Big News: TROP2 Research Reveals Another Potential Advantage for REQORSA

The November 19 announcement highlights findings from research titled "TROP2 Predicts Response to TUSC2 Gene Therapy and Its Modulation Sensitizes Non-Small Cell Lung Cancer to Treatment."

Researchers evaluated multiple NSCLC cell lines and patient-derived organoid models to investigate the relationship between TROP2 expression and response to TUSC2 gene delivery.

The findings were particularly noteworthy:
  • Approximately 50% of the 10 NSCLC cell lines evaluated demonstrated primary resistance to TUSC2 gene delivery.
  • Approximately 50% of the 12 patient-derived organoid models also demonstrated primary resistance.
  • Low TROP2 protein expression was consistently associated with primary resistance across multiple preclinical models.
  • Analysis of pretreatment tumor biopsies from patients enrolled in a TUSC2 gene therapy clinical trial provided additional supporting evidence.

Perhaps the most intriguing aspect involved experiments examining whether changing TROP2 expression could influence treatment sensitivity.

Researchers introduced TROP2 into TROP2-low NSCLC cancer cells, including H460 and H1299 models. This significantly increased TUSC2-induced apoptosis, bringing the response to levels similar to cells naturally expressing higher TROP2.

This is an important scientific observation because it suggests TROP2 may have a role beyond simply identifying tumors that respond differently. Modifying its expression could potentially become another research strategy for enhancing REQORSA treatment.

The company believes these findings could help inform future patient-selection strategies and additional research into improving treatment response.

Roche Diagnostics Collaboration: A Powerful Addition to Genprex's Strategy

One of Genprex's most important strategic developments remains its collaboration with Roche Diagnostics, announced August 3.

The collaboration focuses on validating biomarker assays for non-small cell lung cancer, with particular attention to TROP2 and PTEN.

Roche brings extensive diagnostic expertise to the relationship, while Genprex contributes its developing REQORSA gene therapy platform and growing body of clinical and preclinical research.

The objective is to develop a more refined approach to identifying patients who may be more likely to benefit from REQORSA.

Previous clinical research suggested that higher TROP2 expression and lower PTEN expression were associated with longer progression-free survival in certain NSCLC patient groups.

Today's new findings add another important scientific component to this collaboration by providing additional evidence supporting the investigation of TROP2 as a potential predictive biomarker.

Genprex anticipated completing the Roche-related assay validation studies around the end of 2026, with potential incorporation into its NSCLC clinical program following successful validation.

The combination of Roche's diagnostic capabilities and Genprex's gene therapy research could become an important part of the company's precision-medicine strategy.

REQORSA: Advancing an Innovative Approach to Lung Cancer

At the center of Genprex's oncology platform is REQORSA, also known as quaratusugene ozeplasmid.

The investigational therapy is designed to deliver the TUSC2 tumor-suppressor gene into cancer cells using Genprex's proprietary ONCOPREX Delivery System, which utilizes lipid-based nanoparticles.

TUSC2 expression is reduced or absent in more than 80% of NSCLC cases and nearly all small cell lung cancers, making it an important target for investigation.

REQORSA is designed to restore tumor-suppressor activity and influence multiple biological pathways involved in cancer progression, including MAPK and mTOR signaling, cell-cycle regulation and programmed cancer-cell death.

Genprex is advancing two important clinical initiatives:

Acclaim-1: Evaluating REQORSA in combination with AstraZeneca's Tagrisso in patients with advanced NSCLC carrying specific EGFR mutations.

Acclaim-3: Evaluating REQORSA in an extensive-stage small cell lung cancer treatment strategy.

Both programs have received FDA Fast Track designation, while the small cell lung cancer program has also received Orphan Drug Designation.

New TUSC2 Research Expands the Scientific Story

Genprex has also been generating interest through its sponsored research collaboration with Meharry Medical College.

Recent research has examined TUSC2's role in cellular resilience, mitochondrial function and biological processes associated with aging.

On November 5, the company highlighted patient-derived research involving blood samples from 11 lung cancer patients receiving REQORSA. Researchers identified changes in gene-expression patterns associated with mitochondrial adaptation, autophagy, cellular maintenance and protein quality control.

These findings add another dimension to the understanding of TUSC2's biological activity in humans and complement the company's broader scientific investigation.

Diabetes Gene Therapy Adds Another Development Opportunity

Beyond oncology, Genprex is pursuing an additional opportunity through its diabetes gene therapy program.

The approach uses AAV technology to deliver Pdx1 and MafA genes to the pancreas, with the objective of restoring insulin-producing cell function.

Preclinical studies have produced encouraging findings in Type 1 and Type 2 diabetes models, including improvements in glucose control and insulin-related measures.

In August, Genprex announced the selection of a U.S.-based contract development and manufacturing organization to begin manufacturing scale-up for its diabetes gene therapy candidate.

This provides another important development program as the company works toward future clinical research.

The Road Ahead: Important Catalysts for GNPX Investors

Genprex has several important developments to watch as 2026 progresses:
  • Continued investigation of TROP2 as a potential predictive biomarker for REQORSA.
  • Further research into whether TROP2 modulation can enhance treatment sensitivity.
  • Anticipated completion of Roche Diagnostics biomarker assay validation.
  • Continued advancement of the Acclaim-1 and Acclaim-3 clinical programs.
  • Additional TUSC2 research and diabetes gene therapy development.

Genprex Is Building an Intriguing Precision Gene Therapy Platform

Today's November 19 announcement adds another important milestone to Genprex's developing story. The TROP2 findings are particularly interesting because they suggest two potential opportunities: identifying patients more likely to respond to REQORSA and investigating whether changing TROP2 expression could increase treatment sensitivity.

Combined with the Roche Diagnostics collaboration, these findings strengthen the scientific foundation behind Genprex's precision-oncology ambitions.

The company's continued TUSC2 research, advancing lung cancer clinical programs and separate diabetes gene therapy initiative provide multiple areas of development to follow.

For investors watching emerging biotechnology opportunities, Genprex is building an increasingly compelling story around innovative gene therapy, strategic diagnostic collaboration and personalized cancer treatment. With today's new TROP2 findings adding another exciting dimension to REQORSA, GNPX has important scientific milestones ahead as it works to translate its research into meaningful clinical progress.

For more information on $GNPX visit: www.genprex.com and https://compasslivemedia.com/gnpx/

Media Contact:
Company Name: Genprex, Inc.
Contact: Kalyn Dabbs
Email: [email protected]
Phone: (877) 774-GNPX (4679)
Country: United States
Website: www.genprex.com

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website

Contact
CorporateAds
***@gmail.com

Photos: (Click photo to enlarge)




Source: CorporateAds

Read Full Story - BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy | More news from this source

Press release distribution by PRLog
MORE NEWS
Korean tech giants take different paths in humanoid robot race
Nov 19, 2026
Korean tech giants take different paths in humanoid robot race

Samsung Electronics and LG Electronics are pursuing markedly different strategies in the robotics market, and the contrast is expected to become more apparent as the two companies showcase their latest technologies and visions at CES 2027. According to industry officials on Thursday, Samsung Electronics is focusing on precise control of robotic hands and arms, as dexterity is considered one of the most critical capabilities for expanding the practical applications of humanoid robots. Unlike conventional robots, whose role was repeating a single rigid motion, humanoid robots are required to perform various work in constantly changing real-world environments. This requires them to go beyond simply grasping and moving objects to handling a wide range of tools and components with precision. The challenge becomes even greater when dealing with delicate and fragile components, which demand increasingly precise control of robotic fingers and arms. To achieve this, Samsung Electronics' newly established Robotics Experience Division is reportedly focusing on tendon-driven technologies that use ac

Diageo Korea unveils 2027 Year of the Red Sheep Johnnie Walker Blue Label
Nov 19, 2026
Diageo Korea unveils 2027 Year of the Red Sheep Johnnie Walker Blue Label

Diageo Korea unveiled a limited-edition Johnnie Walker Blue Label to welcome 2027, pairing its flagship Scotch with bespoke artwork celebrating hope and new beginnings. Released earlier this week, the special bottling is the latest chapter in Johnnie Walker’s annual zodiac collection, a series known for reimagining each year’s animal symbol through distinct artistic collaborations. The limited edition marks the Year of the Red Sheep, also referred to as the Year of the Goat. The latest edition was created in collaboration with Jiayi Li, a Chinese artist based in Paris, whose design draws on the red sheep as a symbol of warmth, dignity and vitality. The packaging connects the animal's gentle appearance and inner determination with Johnnie Walker's longstanding "Keep Walking" philosophy, which emphasizes perseverance and moving toward new possibilities. The limited edition also includes a footprint kit containing an ink pad and acrylic frame, allowing parents to preserve newborns' footprints as a keepsake for babies born in 2027. The addition is intended to make the bottle a commemorati

Internal trading by large biz groups remains high in 2025: regulator
Nov 19, 2026
Internal trading by large biz groups remains high in 2025: regulator

Transactions among affiliates of large business groups still remained high last year amid government efforts to regulate such practices and increased sales, the antitrust regulator said Thursday. According to the Fair Trade Commission (FTC), the total value of inter-affiliate transactions by conglomerates amounted to 841 trillion won ($631 billion) last year. A total of 102 business groups with 2,871 affiliates are subject to the disclosure of their internal trading, with their assets exceeding 5 trillion won, according to the regulator. The proportion of such trading to overall sales by those business groups stood at 35 percent, according to the FTC. Internal trading within family-run conglomerates, known as chaebol, has often been criticized for enabling owner families to secure significant profits by awarding lucrative contracts to their subsidiaries. The FTC highlighted that affiliates with high ownership stakes held by second-generation family members saw a sharp rise in internal trading last year. The government has encouraged family-run conglomerates to transition into holding compa

Kolmar Group secures Red Bull's Korean distribution rights
Nov 19, 2026
Kolmar Group secures Red Bull's Korean distribution rights

Kolmar Group has secured the Korean distribution rights for Red Bull, the world's No. 1 energy drink brand, as Vice Chairman Yoon Sang-hyun seeks to capitalize on the fast-growing market by adding the Austrian brand to HK inno.N's business portfolio. HK inno.N plans to leverage its nationwide distribution network and experience in building Condition, a popular Korean hangover relief drink, into one of the country's leading brands to expand Red Bull's market share. Launched in Austria in 1987, Red Bull sold approximately 14 billion cans worldwide last year, up 10.2 percent from a year earlier. Its revenue rose 8.6 percent to a record 12.2 billion euros ($14.1 billion). The global energy drink market is also expanding rapidly. According to market research firm Grand View Research, the market was valued at $85.3 billion last year and is projected to reach $158.5 billion by 2033, representing an average annual growth rate of 8.1 percent. Korea's energy drink market is also growing strongly despite a slowdown in overall beverage consumption. Lotte Chilsung Beverage's energy drink sales rose 1

LG Group retains faith in existing leadership, promotes AI, robotics talent
Nov 19, 2026
LG Group retains faith in existing leadership, promotes AI, robotics talent

LG Group launched its executive reshuffle on Thursday, retaining its key affiliate CEOs while promoting executives specializing in robotics and artificial intelligence (AI). According to LG Electronics, a total of 44 executives were promoted in the latest reshuffle, including two presidents and three executive vice presidents and 10 senior vice presidents, up from 33 promotions last year. The reshuffle will take effect on Jan. 1. Baek Seung-tae, head of LG Electronics' Home Appliance Solution (HS) division, was promoted to president in recognition of his role in driving the division's growth despite challenging market conditions, including tariff pressures and rising raw material costs. Baek joined LG Electronics in 1990 and has served as head of its Living Solution and Kitchen Solution businesses. Since taking charge of the HS division last year, he has strengthened LG Electronics’ competitiveness despite unfavorable market conditions. He is now accelerating preparations for future growth, including efforts to commercialize robotic actuators. Lee Sang-woo, management strategy head of

LG Display scraps $2.25 bil. OLED investment plan
Nov 19, 2026
LG Display scraps $2.25 bil. OLED investment plan

LG Display said Thursday it has scrapped its plan to invest 3 trillion won ($2.25 billion) in a production line for large organic light-emitting diode (OLED) panels in South Korea. The decision came seven years after the display panel maker under LG Group announced plans in 2019 to build a 10.5-generation OLED production line in Paju, north of Seoul. In 2023, the company extended the investment completion deadline by five years to 2028, citing the COVID-19 pandemic and global economic uncertainties. In a regulatory filing, LG Display attributed its latest decision to significant changes in "uncontrollable external conditions" and market dynamics, citing the pandemic, geopolitical conflicts, high inflation and elevated interest rates. The company also pointed to a prolonged downturn in the large OLED panel market amid slowing OLED TV demand and a slower-than-expected transition from liquid crystal displays (LCDs) to OLEDs.

Korea's largest game show G-STAR at crossroads as top studios look abroad
Nov 19, 2026
Korea's largest game show G-STAR at crossroads as top studios look abroad

Launched in 2005, G-STAR has been widely considered a barometer of South Korea's gaming industry, giving developers a stage to debut upcoming titles, and facilitating cross-border exchanges between local studios and overseas publishers. Despite ups and downs, including a complete cancellation during the COVID-19 pandemic, the annual event has maintained its reputation as South Korea's flagship game fair. After two decades, however, the event is now at a crossroads. Despite efforts to expand its scope into other sectors, such as webtoons and motor racing, major domestic game companies are turning away from the event and visitor numbers are declining. Three of the country's biggest game companies -- NC Corp., Netmarble Corp. and Nexon Games Co. -- were absent from this year's G-STAR, which kicked off its three-day run in the southeastern port city of Busan on Thursday. Nexon and NC served as the event's main sponsors in 2024 and 2025, respectively. It marked the first time the three game giants bypassed the event since 2021, when the country was reeling from the COVID-19 pandemic. Krafton In

‘Too high, but I’d still buy’: Anthropic IPO entices Chinese investors despite barriers
Nov 19, 2026
‘Too high, but I’d still buy’: Anthropic IPO entices Chinese investors despite barriers

For Cecilia Yang, a 28-year-old consultant in the eastern Chinese city of Hangzhou, Claude has become an indispensable daily colleague. So when the AI chatbot’s creator, Anthropic, priced its blockbuster initial public offering (IPO) on Wednesday, she decided she wanted a piece of the company, even if the valuation made her wince. “The IPO price is too high,” Yang said. “But I’d still buy a small amount just to take part and support Claude, my go-to work companion.” Yang’s enthusiasm reflects a...

After Jensen Huang’s exit, Nvidia speeds up pay reviews. Will it help retain staff?
Nov 19, 2026
After Jensen Huang’s exit, Nvidia speeds up pay reviews. Will it help retain staff?

Some Nvidia employees in China have shrugged off management’s promise to accelerate pay reviews – made at the US chipmaker’s first all-hands meeting since Jensen Huang’s departure – clinging instead to hopes of the founder’s eventual return. At Wednesday’s roughly 50-minute town hall, interim CEO Colette Kress said annual pay reviews – usually held in March – would now take place in December. Executives also pledged to maintain existing business and supply-chain relationships, according to a...

Watch: The Hill's Capitol Crypto Forum
Nov 19, 2026
Watch: The Hill's Capitol Crypto Forum

A new generation of financial infrastructure is taking shape through the development of blockchain networks and dollar-backed tokens known as stablecoins. Central to this evolution is the Clarity Act — a comprehensive landmark bill that would create a U.S. regulatory framework for the cryptocurrency industry. While the House voted to advance the Digital Asset Market...

Alibaba accelerates pivot to in-house chips after reporting jump in sales
Nov 19, 2026
Alibaba accelerates pivot to in-house chips after reporting jump in sales

Alibaba Group Holding is accelerating its pivot to domestic microchips, as chief executive Eddie Wu Yongming said the company was training its next-generation AI models on in-house chips after reporting a better-than-expected uptick in revenue and profit. “Infrastructure powered by our own domestically developed chips is becoming the foundation of Alibaba’s full-stack AI capabilities,” Wu said on Thursday during an earnings call, adding that the company’s proprietary chip development was...

Policymakers view Anthropic's looming IPO with wary eye
Nov 19, 2026
Policymakers view Anthropic's looming IPO with wary eye

Lawmakers are watching Anthropic's stock market debut with a wary eye, as the AI giant prepares for a massive initial public offering (IPO) at a moment of upheaval and uncertainty for the industry. Anthropic is poised to make its public debut Thursday in what is widely expected to be one of the biggest IPOs of the year. But...

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

About Us

Always dynamic, always updated, The Witness Daily ensures minute-by-minute update to the most pressing issues, curated specifically to cater to critical newsreaders of our time.

Copyright © 2015 - 2026 Redshift Daily. All Rights Reserved.